388 related articles for article (PubMed ID: 22130164)
1. Ipilimumab in treatment-naive and previously treated patients with metastatic melanoma: retrospective analysis of efficacy and safety data from a phase II trial.
Thompson JA; Hamid O; Minor D; Amin A; Ron IG; Ridolfi R; Assi H; Berman D; Siegel J; Weber JS
J Immunother; 2012 Jan; 35(1):73-7. PubMed ID: 22130164
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma.
Weber J; Thompson JA; Hamid O; Minor D; Amin A; Ron I; Ridolfi R; Assi H; Maraveyas A; Berman D; Siegel J; O'Day SJ
Clin Cancer Res; 2009 Sep; 15(17):5591-8. PubMed ID: 19671877
[TBL] [Abstract][Full Text] [Related]
3. Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial.
Weber JS; Amin A; Minor D; Siegel J; Berman D; O'Day SJ
Melanoma Res; 2011 Dec; 21(6):530-4. PubMed ID: 22051508
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials.
Schadendorf D; Wolchok JD; Hodi FS; Chiarion-Sileni V; Gonzalez R; Rutkowski P; Grob JJ; Cowey CL; Lao CD; Chesney J; Robert C; Grossmann K; McDermott D; Walker D; Bhore R; Larkin J; Postow MA
J Clin Oncol; 2017 Dec; 35(34):3807-3814. PubMed ID: 28841387
[TBL] [Abstract][Full Text] [Related]
5. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.
Graziani G; Tentori L; Navarra P
Pharmacol Res; 2012 Jan; 65(1):9-22. PubMed ID: 21930211
[TBL] [Abstract][Full Text] [Related]
6. Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma.
Weber JS; Hamid O; Chasalow SD; Wu DY; Parker SM; Galbraith S; Gnjatic S; Berman D
J Immunother; 2012 Jan; 35(1):89-97. PubMed ID: 22130166
[TBL] [Abstract][Full Text] [Related]
7. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial.
Di Giacomo AM; Ascierto PA; Pilla L; Santinami M; Ferrucci PF; Giannarelli D; Marasco A; Rivoltini L; Simeone E; Nicoletti SV; Fonsatti E; Annesi D; Queirolo P; Testori A; Ridolfi R; Parmiani G; Maio M
Lancet Oncol; 2012 Sep; 13(9):879-86. PubMed ID: 22894884
[TBL] [Abstract][Full Text] [Related]
8. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma.
Berman D; Parker SM; Siegel J; Chasalow SD; Weber J; Galbraith S; Targan SR; Wang HL
Cancer Immun; 2010 Nov; 10():11. PubMed ID: 21090563
[TBL] [Abstract][Full Text] [Related]
9. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma.
Prieto PA; Yang JC; Sherry RM; Hughes MS; Kammula US; White DE; Levy CL; Rosenberg SA; Phan GQ
Clin Cancer Res; 2012 Apr; 18(7):2039-47. PubMed ID: 22271879
[TBL] [Abstract][Full Text] [Related]
10. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma.
Hersh EM; O'Day SJ; Powderly J; Khan KD; Pavlick AC; Cranmer LD; Samlowski WE; Nichol GM; Yellin MJ; Weber JS
Invest New Drugs; 2011 Jun; 29(3):489-98. PubMed ID: 20082117
[TBL] [Abstract][Full Text] [Related]
11. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.
Lynch TJ; Bondarenko I; Luft A; Serwatowski P; Barlesi F; Chacko R; Sebastian M; Neal J; Lu H; Cuillerot JM; Reck M
J Clin Oncol; 2012 Jun; 30(17):2046-54. PubMed ID: 22547592
[TBL] [Abstract][Full Text] [Related]
12. Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery.
Mathew M; Tam M; Ott PA; Pavlick AC; Rush SC; Donahue BR; Golfinos JG; Parker EC; Huang PP; Narayana A
Melanoma Res; 2013 Jun; 23(3):191-5. PubMed ID: 23462208
[TBL] [Abstract][Full Text] [Related]
13. Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials.
Wolchok JD; Weber JS; Hamid O; Lebbé C; Maio M; Schadendorf D; de Pril V; Heller K; Chen TT; Ibrahim R; Hoos A; O'Day SJ
Cancer Immun; 2010 Oct; 10():9. PubMed ID: 20957980
[TBL] [Abstract][Full Text] [Related]
14. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma.
Hamid O; Schmidt H; Nissan A; Ridolfi L; Aamdal S; Hansson J; Guida M; Hyams DM; Gómez H; Bastholt L; Chasalow SD; Berman D
J Transl Med; 2011 Nov; 9():204. PubMed ID: 22123319
[TBL] [Abstract][Full Text] [Related]
15. Ipilimumab: a novel treatment for metastatic melanoma.
Culver ME; Gatesman ML; Mancl EE; Lowe DK
Ann Pharmacother; 2011 Apr; 45(4):510-9. PubMed ID: 21505108
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.
Di Giacomo AM; Danielli R; Guidoboni M; Calabrò L; Carlucci D; Miracco C; Volterrani L; Mazzei MA; Biagioli M; Altomonte M; Maio M
Cancer Immunol Immunother; 2009 Aug; 58(8):1297-306. PubMed ID: 19139884
[TBL] [Abstract][Full Text] [Related]
17. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
Robert C; Thomas L; Bondarenko I; O'Day S; Weber J; Garbe C; Lebbe C; Baurain JF; Testori A; Grob JJ; Davidson N; Richards J; Maio M; Hauschild A; Miller WH; Gascon P; Lotem M; Harmankaya K; Ibrahim R; Francis S; Chen TT; Humphrey R; Hoos A; Wolchok JD
N Engl J Med; 2011 Jun; 364(26):2517-26. PubMed ID: 21639810
[TBL] [Abstract][Full Text] [Related]
18. Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade.
Boasberg P; Hamid O; O'Day S
Semin Oncol; 2010 Oct; 37(5):440-9. PubMed ID: 21074058
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant therapy for resected stage III melanoma patients: high-dose interferon-alpha versus ipilimumab combined with kinases inhibitors.
Minutilli E; Feliciani C
Tumori; 2012; 98(2):185-90. PubMed ID: 22677983
[TBL] [Abstract][Full Text] [Related]
20. Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy.
Danielli R; Ridolfi R; Chiarion-Sileni V; Queirolo P; Testori A; Plummer R; Boitano M; Calabrò L; Rossi CD; Giacomo AM; Ferrucci PF; Ridolfi L; Altomonte M; Miracco C; Balestrazzi A; Maio M
Cancer Immunol Immunother; 2012 Jan; 61(1):41-8. PubMed ID: 21833591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]